Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Shares of Moderna Inc. MRNA, -6.07% took a 5.9% beating toward a three-year low in afternoon trading Tuesday, enough to lead the S&P 500's SPX, -0.21% losers, and to put them on track to suffer yet another five-day losing streak. The biotechnology and COVID vaccine company's stock has shed 17.2% during its current losing streak, the worst five-day performance since it plunged 19.2% during the five-day stretch that ended Feb. 24, 2023.

Moderna's stock pummeled to pace the S&P 500's decliners, as it heads for yet another 5-day losing streak

Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.

Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View

Moderna (MRNA) was the worst-performing stock in the S&P 500 on Monday as shares lost over 6% after the biotech firm said it “remains comfortable” with its full-year guidance, but warned that it couldn't predict exact demand for its COVID-19 vaccines yet. The comments came after rival Pfizer (PFE) slashed its full-year outlook “Solely due to COVID products.

Moderna Shares Slump Amid Concerns About COVID-19 Vaccine Demand

Shares of Moderna Inc. extended their slide Monday toward a fourth straight loss, a streak whose start coincided with a sale of shares by company co-founder and chair Noubar Afeyan.

Moderna's stock slides to three-year low as co-founder sells more shares

In trading on Monday, shares of Moderna entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $90.18 per share.

Moderna Becomes Oversold

BioNTech SE

Pfizer

Moderna stock and BioNTech stock led a sell-off Monday among Covid vaccine makers after Pfizer slashed its full-year guidance.

Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion

With its shares under pressure due to revised COVID guidance from Pfizer Inc. PFE, +3.38%, Moderna Inc. MRNA, -3.19% on Monday said it “remains comfortable” with its existing guidance on full-year 2023 COVID-19 sales.

Moderna confirms COVID sales guidance as shares sink on Pfizer news

Moderna on Monday reaffirmed its forecast of $6 billion to $8 billion in COVID vaccine sales for the year, after rival Pfizer slashed forecast for its vaccine last week.

Moderna reaffirms annual COVID vaccine sales forecast

Novavax

Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.

Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

Hubbell

Lululemon Athletica

Manchester United

Shares of Lululemon Athletica Inc. LULU, +1.00% rallied more than 5% after index provider S&P Dow Jones Indices said the stock will join the S&P 500 index SPX on Wednesday.

Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move

Airbnb

Carvana

GameStop

Lucid Group

Peloton

QUALCOMM

Even as the end of 2023 is still months away, now may be the time to figure out which stocks to sell ahead of 2024. All bets are off whether stocks can end the year on a high note.

Don't Hold On: 7 Stocks to Sell Before 2024

Recursion Pharmaceuticals

The AI in healthcare market may be worth more than $190 billion by the end of this decade, making it a great place to look for investing opportunities. It's important to consider the whole picture when choosing a stock instead of betting only on the company's AI program.

1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid

CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.

Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023

ARK Innovation ETF

Roku

October is renowned for its potential to unsettle investors with significant market drops, a trend that continues from the previous month. Indeed, while certain stocks have shown an ability to weather volatility, some falling stocks are down and could still see greater declines.

3 Stocks That Are Down Big, But Are Due to Fall Much Further

Is Moderna stock a buy after the company announced positive results for its flu shot? Is MRNA stock a buy right now?

Is Moderna Stock A Buy As Its Case For A New Flu Vaccine Finally Pans Out?

Vaccine stocks delivered multibagger returns earlier in the pandemic. Their performance has suffered in recent times as some investors worry about revenue in a post-pandemic world.

The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?

Dollar General

Mullen Automotive

Uncertainty abounds in the market right now. Whether driven by fears tied to surging inflation, rising interest rates, or geopolitical turmoil, investors have plenty to consider moving forward.

3 Shaky Stocks to Sell in October Before It's Too Late

Doximity

Moderna predicts billions of dollars in revenue -- and from multiple products -- in the not-too-distant future. Doximity has a solid earnings track record and is launching new tools to keep clients coming back.

These 2 Top Stocks Are Screaming Buys Right Now

AstraZeneca

Merck

CRISPR Therapeutics

GlaxoSmithKline

Novartis

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

Illumina

Johnson & Johnson

UnitedHealth Group

Zimmer Biomet Hlds

With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows, and future earnings potential.

3 Undervalued Healthcare Stocks to Watch as Sector Struggles

Moderna just reported positive data from its combined flu/coronavirus vaccine candidate and aims to launch a phase 3 trial. The potential product could appeal to people who already go for flu vaccines -- that's about half of Americans.

Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market?

Moderna is a biotech company with high potential upside, despite the decline in demand for its COVID-19 vaccine. The company's mRNA platform approach has advantages over traditional vaccine manufacturing methods. Moderna has a large drug pipeline and plans to launch 15 new mRNA-based medicines over the next five years.

Investing In Moderna: A Speculative Buy For Long-Term Gains

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

Moderna Therapeutics Inc (NASDAQ:MRNA) has filed a new drug submission for its vaccine aimed at preventing respiratory syncytial virus (RSV) in adults aged 60 and older with Health Canada, according to a report by MarketWatch. According to the report, the regulatory submission is based on positive data from a prespecified interim analysis of its ConquerRSV study, which included 37,000 adults aged 60 and older across 22 countries.

Moderna reportedly files submission for RSV vaccine with Health Canada

mRNA-1345 is an investigational vaccine for the prevention of RSV in adults aged 60 years or older TORONTO, ON / ACCESSWIRE / October 5, 2023 / Moderna Biopharma Canada Corp. today announced the filing of a New Drug Submission (NDS) to Health Canada for mRNA-1345, its investigational vaccine candidate for the prevention of RSV in adults aged 60 years or older. This is the first mRNA vaccine candidate for RSV filed in Canada.

News for Moderna Stock (MRNA)